Dear Editor,Glioblastoma(GBM)is a lethal primary brain cancer,with a median survival of less than 2 years.1 Immune checkpoint blockades(ICBs)have revolutionized cancer therapy in the last decade,but they have little c...Dear Editor,Glioblastoma(GBM)is a lethal primary brain cancer,with a median survival of less than 2 years.1 Immune checkpoint blockades(ICBs)have revolutionized cancer therapy in the last decade,but they have little clinical benefit in GBM.1 Genomic and transcriptomic analysis revealed a significant enrichment of PTEN mutations in GBM patients resistant to ICBs.2 PTEN deficiency activates the phosphatidylinositol 3-kinase(PI3K)-AKT pathway to shape an immunosuppressive microenvironment.展开更多
基金The work is supported by tWwhe National Natural Science Foundation of China(NSFC Grant#81620108020�,to D.G.,Grant#81803568,to F.X.,Grant#31800151,to J.W.)Guangdong Zhujiang Talents Program(to D.G.)+2 种基金Natural Science Foundation of Guangdong Province(Grant#2018A030310099 to F.X.)Shenzhen Science and Technology Program(Grant#KQTD20180411143323605 and#JSGG20200225150431472 to D.G.,Grant#JCYJ20170818162249554,to FX)National Ten-thousand Talents Program(to D.G.).
文摘Dear Editor,Glioblastoma(GBM)is a lethal primary brain cancer,with a median survival of less than 2 years.1 Immune checkpoint blockades(ICBs)have revolutionized cancer therapy in the last decade,but they have little clinical benefit in GBM.1 Genomic and transcriptomic analysis revealed a significant enrichment of PTEN mutations in GBM patients resistant to ICBs.2 PTEN deficiency activates the phosphatidylinositol 3-kinase(PI3K)-AKT pathway to shape an immunosuppressive microenvironment.
